Business Context and Reporting Period
This Form 8-K Current Report was filed by Milestone Pharmaceuticals Inc. on September 21, 2020. The filing discloses corporate governance changes, specifically the election of two new directors to the Board of Directors, effective October 1, 2020.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change is the expansion of the Board of Directors with the addition of Lisa M. Giles and Robert J. Wills, Ph.D. Ms. Giles will join the Audit Committee, replacing Debra Liebert, while Dr. Wills will join the Nominating & Corporate Governance Committee.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. Management commentary is limited to the qualifications of the new directors and the terms of their appointment.
- Lisa M. Giles Compensation: $35,000 annual cash retainer plus $7,500 for Audit Committee service. She will receive an option to purchase 30,000 common shares vesting over three years.
- Robert J. Wills Compensation: $35,000 annual cash retainer plus $4,000 for Nominating & Corporate Governance Committee service. He will receive an option to purchase 30,000 common shares vesting over three years.
- Equity Terms: Initial grants are subject to the 2019 Equity Incentive Plan and vest in equal monthly installments over three years, contingent on continued service.
Investor Verification Checklist
- Verify the effective date of the new directors' terms (October 1, 2020) and their expiration at the 2021 annual meeting.
- Confirm the specific committee assignments: Ms. Giles to the Audit Committee and Dr. Wills to the Nominating & Corporate Governance Committee.
- Review the 2019 Equity Incentive Plan to understand the full terms of the 30,000 share options granted to each new director.
- Check for any subsequent filings regarding the resignation of Debra Liebert from the Audit Committee.